Active	Status	Sponsor type	Region	Phase	Filter
5 Active 6 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
VesiGel (mitomycin intravesicular) / UroGen
NCT05136898: Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)	Completed	3	8	US	UGN-102, UGN-102 (mitomycin) for intravesical solution	UroGen Pharma Ltd.	Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder	02/23	02/23
ATLAS, NCT04688931: A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer	Terminated	3	282	Europe, US, RoW	UGN-102, UGN-102 (mitomycin) for intravesical solution, TURBT, Transurethral resection of bladder tumors	UroGen Pharma Ltd.	Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder	03/23	03/23
2020-003541-11: An Open Study of the Efficacy, Durability, and Safety of a new drug in Patients with Bladder Cancer (ATLAS)	Not yet recruiting	3	632	Europe, RoW	UGN-102 (Mitomycin) for Solution, UGN-102, Powder for intravesical solution	UroGen Pharma Ltd., UroGen Pharma Ltd.	Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Diseases [C] - Cancer [C04]
ENVISION, NCT05243550 / 2021-005948-29: A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer	Active, not recruiting	3	240	Europe, US, RoW	UGN-102, UGN-102 (mitomycin) for intravesical solution	UroGen Pharma Ltd.	Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder	04/23	02/28
UTOPIA, NCT06331299: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer	Recruiting	3	87	US	UGN-103, UGN-103 (mitomycin) for intravesical solution	UroGen Pharma Ltd.	Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder	03/25	03/26